Rallybio Corporation – NASDAQ:RLYB
Rallybio stock price today
$0.569
-0.34
-37.72%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 16 minutes
Rallybio stock price monthly change
-33.77%
month
Rallybio stock price quarterly change
-33.77%
quarter
Rallybio stock price yearly change
-64.85%
year
Rallybio key metrics
Market Cap | 41.07M |
Enterprise value | 96.02M |
P/E | -2.37 |
EV/Sales | N/A |
EV/EBITDA | -1.46 |
Price/Sales | N/A |
Price/Book | 0.90 |
PEG ratio | 0.08 |
EPS | -1.88 |
Revenue | N/A |
EBITDA | -80.27M |
Income | -76.27M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeRallybio stock price history
Rallybio stock forecast
Rallybio financial statements
| Jun 2023 | 0 | -18.63M | |
|---|---|---|---|
| Sep 2023 | 0 | -18.37M | |
| Dec 2023 | 228K | -20.24M | -8878.07% |
| Mar 2024 | 0 | -19.02M |
| Dec 2023 | 228K | -20.24M | -8878.07% |
|---|---|---|---|
| Mar 2024 | 0 | -19.02M | |
| Oct 2025 | 0 | -14.06M | |
| Dec 2025 | 0 | -14.88M |
Analysts Price target
Financials & Ratios estimates
| 2023-03-06 | -0.63 | -0.46 |
|---|---|---|
| 2023-05-09 | -0.5 | -0.43 |
| 2023-08-08 | -0.48 | -0.46 |
| 2023-11-09 | -0.51 | -0.45 |
| Jun 2023 | 147576000 | 8.31M | 5.64% |
|---|---|---|---|
| Sep 2023 | 133194000 | 9.61M | 7.22% |
| Dec 2023 | 115620000 | 9.43M | 8.16% |
| Mar 2024 | 99359000 | 10.20M | 10.27% |
| Jun 2023 | -13.38M | 6.21M | 210K |
|---|---|---|---|
| Sep 2023 | -16.47M | 3.07M | 0 |
| Dec 2023 | -11.64M | 16.90M | 72K |
| Mar 2024 | -15.45M | 10.26M | 0 |
Rallybio alternative data
| Aug 2023 | 43 |
|---|---|
| Sep 2023 | 45 |
| Oct 2023 | 45 |
| Nov 2023 | 45 |
| Dec 2023 | 44 |
| Jan 2024 | 44 |
| Feb 2024 | 44 |
| Mar 2024 | 43 |
| Apr 2024 | 43 |
| May 2024 | 43 |
| Jun 2024 | 30 |
| Jul 2024 | 30 |
Rallybio other data
48.80%
-51.20%
of RLYB is owned by hedge funds
32
-25
15.52M
-16.78M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2022 | 0 | 200000 |
| Jun 2022 | 0 | 300000 |
| Nov 2022 | 3333388 | 0 |
| Mar 2023 | 5000 | 200000 |
| Insider | Compensation |
|---|---|
Dr. Stephen Uden M.B, M.D. (1958) Pres, Chief Operating Officer & Chief Scientific Officer | $545,460 |
Mr. Jeffrey M. Fryer CPA (1969) Chief Financial Officer & Treasurer | $545,460 |
| Dr. Martin W. MacKay Ph.D. (1956) Chief Executive Officer & Chairman | $545,460 |
-
What's the price of Rallybio stock today?
One share of Rallybio stock can currently be purchased for approximately $0.57.
-
When is Rallybio's next earnings date?
Unfortunately, Rallybio's (RLYB) next earnings date is currently unknown.
-
Does Rallybio pay dividends?
No, Rallybio does not pay dividends.
-
How much money does Rallybio make?
Rallybio has a market capitalization of 41.07M. Rallybio made a loss 74.56M US dollars in net income (profit) last year or -$0.45 on an earnings per share basis.
-
What is Rallybio's stock symbol?
Rallybio Corporation is traded on the NASDAQ under the ticker symbol "RLYB".
-
What is Rallybio's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Rallybio?
Shares of Rallybio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Rallybio's key executives?
Rallybio's management team includes the following people:
- Dr. Stephen Uden M.B, M.D. Pres, Chief Operating Officer & Chief Scientific Officer(age: 67, pay: $545,460)
- Mr. Jeffrey M. Fryer CPA Chief Financial Officer & Treasurer(age: 56, pay: $545,460)
- Dr. Martin W. MacKay Ph.D. Chief Executive Officer & Chairman(age: 69, pay: $545,460)
-
How many employees does Rallybio have?
As Jul 2024, Rallybio employs 30 workers, which is 30% less then previous quarter.
-
When Rallybio went public?
Rallybio Corporation is publicly traded company for more then 4 years since IPO on 29 Jul 2021.
-
What is Rallybio's official website?
The official website for Rallybio is rallybio.com.
-
Where are Rallybio's headquarters?
Rallybio is headquartered at 234 Church Street, New Haven, CT.
-
How can i contact Rallybio?
Rallybio's mailing address is 234 Church Street, New Haven, CT and company can be reached via phone at +20 3 8593820.
Rallybio company profile:
Rallybio Corporation
rallybio.comExchange:
NASDAQ
Full time employees:
43
Industry:
Biotechnology
Sector:
Healthcare
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
234 Church Street
New Haven, CT 06510
New Haven, CT 06510
CIK: 0001739410
ISIN: US75120L1008
CUSIP: 75120L100
